OMNIVORE: Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma - Rana McKay

May 30, 2020

It is unknown what the optimal duration of nivolumab maintenance is to sustain disease control and what the response rate to single-agent nivolumab is for treatment naïve patients with metastatic renal cell carcinoma (mRCC). OMNIVORE a response-based phase II study seeks to help answer some of these questions. This study enrolled patients with treatment-naïve or previously treated advanced RCC (aRCC) with either clear cell or non-clear cell disease. Prior immune checkpoint inhibitor therapy was not permitted. Rana McKay, joins Alicia Morgans to share the rationale behind the OMNIVORE trial and the aim of the trial investigation of the sequential addition of 2 doses of ipilimumab to induce a response in nivolumab non-responders and duration of nivolumab in responding patients.


Rana R. McKay, MD, Medical Oncologist, Assistant Professor of Medicine, UC San Diego Health

Alicia Morgans, MD, MPH,  Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois